- Home
- EAF vs CAPR Comparison
EAF vs CAPR Comparison
Compare EAF & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EAF
- CAPR
- Stock Information
- Founded
- EAF 1886
- CAPR 2005
- Country
- EAF United States
- CAPR United States
- Employees
- EAF N/A
- CAPR N/A
- Industry
- EAF Industrial Machinery/Components
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EAF Energy
- CAPR Health Care
- Exchange
- EAF Nasdaq
- CAPR Nasdaq
- Market Cap
- EAF 342.1M
- CAPR 324.6M
- IPO Year
- EAF 1995
- CAPR N/A
- Fundamental
- Price
- EAF $17.00
- CAPR $6.20
- Analyst Decision
- EAF Hold
- CAPR Strong Buy
- Analyst Count
- EAF 6
- CAPR 6
- Target Price
- EAF $17.00
- CAPR $23.00
- AVG Volume (30 Days)
- EAF 269.3K
- CAPR 1.1M
- Earning Date
- EAF 10-24-2025
- CAPR 11-12-2025
- Dividend Yield
- EAF N/A
- CAPR N/A
- EPS Growth
- EAF N/A
- CAPR N/A
- EPS
- EAF N/A
- CAPR N/A
- Revenue
- EAF $521,894,000.00
- CAPR $13,392,150.00
- Revenue This Year
- EAF N/A
- CAPR N/A
- Revenue Next Year
- EAF $24.19
- CAPR $7,894.07
- P/E Ratio
- EAF N/A
- CAPR N/A
- Revenue Growth
- EAF N/A
- CAPR N/A
- 52 Week Low
- EAF $5.50
- CAPR $5.68
- 52 Week High
- EAF $25.30
- CAPR $22.90
- Technical
- Relative Strength Index (RSI)
- EAF 57.83
- CAPR 41.58
- Support Level
- EAF $16.42
- CAPR $6.10
- Resistance Level
- EAF $19.00
- CAPR $6.56
- Average True Range (ATR)
- EAF 1.75
- CAPR 0.36
- MACD
- EAF -0.38
- CAPR -0.09
- Stochastic Oscillator
- EAF 39.27
- CAPR 11.18
About EAF GrafTech International Ltd.
GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two product categories: graphite electrodes and petroleum needle coke products. Petroleum needle coke is key raw material used in the production of graphite electrodes.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.